Biogen names two new executives for Bioverativ spinoff
Dr. Vivaldi has more than 20 years of experience in delivering orphan products to patients worldwide, most notably during his tenure at Genzyme Corp., where he applied his medical and professional expertise to lead the company's rare disease business and earned a reputation as a passionate advocate for patients.
Most recently, he served as chief commercial officer at Spark Therapeutics, a gene therapy company, and was co-founder, president and CEO of Minerva Neurosciences.
He received his medical degree from Universidade do Rio de Janeiro Medical School, and completed his residency in endocrinology at Universidade do Estado do Rio de Janeiro and his fellowship at Mount Sinai Hospital Center in New York in the department of genetics.
He received his MBA degree from COPPEAD, Universidade Federal do Rio de Janeiro.
Mr. Greene joins Bioverativ from Willis Group, plc, where he served as chief financial officer, enhancing business analytics and company performance while helping to execute on an ambitious merger and acquisition program.
Previously, he was chief financial officer for HSBC Holdings, earning positions of increasing responsibility over eight years with the company, including Chief Financial Officer for the Global Retail Bank and Wealth Management business.
Earlier in his career, Mr. Greene spent 12 years in various roles at General Electric.
He earned his undergraduate degree from the State University of New York and an MBA from Northwestern University’s Kellogg School of Management.
The spin-off of Bioverativ is on track to be completed in early 2017. ■
What to read next
LATEST MOVES FROM Massachusetts
- bluebird bio appoints Mary Lynne Hedley to board
- Welch's names Lesya Lysyj president, US
- Liberty Mutual appoints Gregg Cunningham as vice president
- Voyager Therapeutics appoints Matthew P. Ottmer as COO
- Ocular Therapeutix appoints Michael Goldstein as CMO
More inside POST